Acute leukemia, a rare but fatal complication after liver transplantation.

Abstract:

:Little information is available about the risk factors and means to improve the survival rate of acute leukemia in a rare but often fatal complication after liver transplantation (LT). We report the development of AML-M2 in one of the 764 patients who underwent liver transplantation at our center, and review the literature on similar cases. The patient, a 42-year-old man who developed acute leukemia 38 months after liver transplantation, was successfully treated with chemotherapy and has subsequently been in remission. With appropriate adjustment of immunosuppressive agents, he was able to safely benefit from chemotherapy. Only 16 patients with acute leukemia after liver transplantation have been reported, and the mortality rate is extraordinarily high (52.94%, 9/17). More cases of acute leukemia will emerge as the rate of survival after liver transplantation increases. The patient's chromosomal mutation profile, the choice of immunosuppressive agent, and infection by hepatitis virus may be the risk factors for the development of acute leukemia after LT. Our experience suggests that clinicians should adjust the immunosuppressive agents according to the immunosuppressive state of the patient and explore the option of reducing or stopping the medication as long as liver function remains stable. These measures could help reduce the high mortality rate among these patients.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Jiang N,Li H,Wang GS,Zhang J,Zhang JF,Yi SH,Yang Y,Cai CJ,Lu MQ,Chen GH

doi

10.1016/j.leukres.2009.03.035

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

1349-51

issue

10

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(09)00164-7

journal_volume

33

pub_type

杂志文章
  • Role of stromal and hematopoietic stem cells in Friend spleen focus forming virus effects in continuous bone marrow culture.

    abstract::Replication of the Friend spleen focus forming virus (SFFV) in C3H/HeJ or C57BL/6J mouse continuous bone marrow cultures is associated with an increased cumulative production of pluripotential/hematopoietic stem cells (CFUs), granulocyte-macrophage progenitor cells (GM-CFUc), and total granulocytes, compared to uninfe...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(83)90133-9

    authors: Greenberger JS,Eckner RJ,Sakakeeny MA,Cohen GI

    更新日期:1983-01-01 00:00:00

  • Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

    abstract::This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.08.009

    authors: Lee SS,Lee JH,Lee JH,Kim DY,Kim SH,Lim SN,Lee YS,Seol M,Ryu SG,Kang YA,Jang S,Park CJ,Chi HS,Yun SC,Lee KH

    更新日期:2009-04-01 00:00:00

  • Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.

    abstract::Increasing evidence suggest that epigenetic mechanisms (e.g. histone modification by histone deacetylases) play a major role in the pathogenesis of Hodgkin's lymphoma (HL). We treated HL cell lines with the histone deacetylase inhibitor vorinostat and investigated the gene expression profile of these cells by using DN...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.02.021

    authors: Kewitz S,Bernig T,Staege MS

    更新日期:2012-06-01 00:00:00

  • Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.

    abstract::Preclinical data suggest that all-trans retinoic acid (ATRA) synergizing with granulocyte colony stimulating factor (G-CSF), can improve the effectiveness of chemotherapy in acute myeloid leukemia (AML). Fludarabine 15 mg/m(2) is the minimum dose able to optimize intensification with fludarabine-arabinosylcytosine reg...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2008.12.014

    authors: Montillo M,Ricci F,Tedeschi A,Cafro AM,Nosari AM,Nichelatti M,Marbello L,Morra E

    更新日期:2009-08-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract::Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0145-2126(96)00116-6

    authors: Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期:1997-02-01 00:00:00

  • Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.

    abstract::The purpose of this study was to determine the relationship between platinum-DNA adducts in leukemic cells and the success of remission induction therapy in adult patients with acute nonlymphocytic leukemia (ANLL). Freshly isolated cells from pre-treatment bone marrow aspirates of 14 patients were incubated with cispl...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/0145-2126(94)90064-7

    authors: Armstrong SG,Browman GP,Benger AM,Meyer RM,McKay KL,Singh G

    更新日期:1994-09-01 00:00:00

  • Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts.

    abstract::The K562 leukemia cell line has been extensively used in studies of erythroid differentiation but it has been less well appreciated that treatment of K562 cells with the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA) leads to loss of their erythroid properties and to acquisition of several megakaryoblastoi...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/0145-2126(90)90002-q

    authors: Alitalo R

    更新日期:1990-01-01 00:00:00

  • Bone marrow B lymphocytes in multiple myeloma and MGUS: Focus on distribution of naïve cells and memory subsets.

    abstract:BACKGROUND/AIMS:Multiple myeloma (MM) is caused by proliferation of clonal plasma cells (cPCs) in bone marrow (BM), associated with numerical and functional defects in immune subsets. An impairment of B cell compartment is involved in onset/progression of the disease. METHODS:By flow cytometry, we studied distribution...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.08.008

    authors: Pojero F,Casuccio A,Giambanco C,Bulati M,Buffa S,Di Bassiano F,Gervasi F,Caruso C,Colonna Romano G

    更新日期:2016-10-01 00:00:00

  • Detection of P glycoprotein activity on normal and leukemic CD34+ cells.

    abstract::Rhodamine 123 is transported by the transmembrane efflux pump P glycoprotein (Pgp). We used this fluorescent dye to study multidrug resistance (MDR) activity in normal and leukemic CD34+ cells. These immature cells had a high degree of MDR activity. Among leukemic cells, CD34+ leukemias had significantly higher MDR ac...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90159-i

    authors: Drenou B,Fardel O,Amiot L,Fauchet R

    更新日期:1993-12-01 00:00:00

  • Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.

    abstract::This 5-year, prospective registry enrolled 600 lower-risk MDS patients (pts) with transfusional iron overload. Clinical outcomes were compared between chelated and nonchelated pts. At baseline, cardiovascular comorbidities were more common in non-chelated pts, and MDS therapy was more common in chelated pts. At 24 mon...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2013.11.004

    authors: Lyons RM,Marek BJ,Paley C,Esposito J,Garbo L,DiBella N,Garcia-Manero G

    更新日期:2014-02-01 00:00:00

  • Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.

    abstract::Appropriate treatment for nonreactive thrombocytosis resulting from a myeloproliferative disorder (MPD) is surrounded by controversy. Although few doubt the association of thrombocytosis with increased risk for life-threatening events such as thrombosis or hemorrhage, or the association between clonal myeloproliferati...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2004.10.002

    authors: Fruchtman SM,Petitt RM,Gilbert HS,Fiddler G,Lyne A,Anagrelide Study Group.

    更新日期:2005-05-01 00:00:00

  • Monoclonal origin of B cells producing k, lambda and k lambda immunoglobulin light chains in a patient with chronic lymphocytic leukemia.

    abstract::Immunoglobulin gene rearrangements can be used as genetic markers of clonality in the study of B-cell populations [4]. We have therefore analysed the structure and expression of heavy and light chain immunoglobulin genes in lymphocytes of a patient with chronic lymphocytic leukemia, where we found both k and lambda pr...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(87)90162-7

    authors: del Senno L,Gandini D,Gambari R,Lanza F,Tomasi P,Castoldi G

    更新日期:1987-01-01 00:00:00

  • Low-dose radiotherapy (2×2 g) versus low doses and rituximab in the treatment of marginal zone b-cell lymphoma previously untreated.

    abstract::Radiotherapy (RT)is considered the treatment of choice in patients with Extra-nodal marginal zone lymphoma (EMZL) at early stage, but the presence of late toxicities has been limited the acceptance. Recently, low doses of RT LDR) (2 x 2 Gy) and the use of limited fields has been observed that retain the efficacy but e...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2020.106443

    authors: Aviles A,Cleto S

    更新日期:2020-11-01 00:00:00

  • The discovery of endothelial progenitor cells. An historical review.

    abstract::Although the earliest sites of hematopoietic cell and endothelial cell differentiation in the yolk sac blood islands were identified about 100 years ago, cells with hemangioblast properties have not yet been identified in vivo. Endothelial cells differentiate from angioblasts in the embryo and from endothelial progeni...

    journal_title:Leukemia research

    pub_type: 历史文章,杂志文章,评审

    doi:10.1016/j.leukres.2006.10.014

    authors: Ribatti D

    更新日期:2007-04-01 00:00:00

  • Differentiation restriction in the neutrophil-granulocyte, macrophage, eosinophil-granulocyte pathway: analysis by equilibrium density centrifugation.

    abstract::Bone marrow culture techniques and equilibrium density centrifugation of human bone marrow cells were used to analyse the neutrophil-granulocyte, macrophage and eosinophil-granulocyte progenitor hierarchy. The buoyant density of progenitor cells changes as cells differentiate down the granulocyte-macrophage pathway an...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90061-3

    authors: Guimaraes JE,Francis GE,Bol SJ,Berney JJ,Hoffbrand AV

    更新日期:1982-01-01 00:00:00

  • Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?

    abstract::Thrombohaemorrhagic complications are major clinical problems in the classical chronic Ph-negative myeloproliferative disorders (CMPDs), polycytaemia vera (PV), essential thrombocythaemia (ET) and idiopathic myelofibrosis (IMF), contributing significantly to morbidity and mortality. Pathophysiologically these disorder...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2005.12.018

    authors: Hasselbalch HC,Riley CH

    更新日期:2006-10-01 00:00:00

  • CD105 and placental growth factor--potent prognostic factors in childhood acute lymphoblastic leukaemia.

    abstract::The studies aimed at identifying a prognostic significance of angiogenesis-related factors: CD105 and placental growth factor (PlGF) in a course of acute lymphoblastic leukaemia (ALL). Research protocol was based on detection of RNA and protein expressions in bone marrow blasts using quantitative PCR and immunocytoche...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.03.017

    authors: Sujka-Kordowska P,Malinska A,Ostalska-Nowicka D,Zabel M,Nowicki M

    更新日期:2012-07-01 00:00:00

  • Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study.

    abstract::In this case-control study, interview data on smoking habits were available for 179 de novo cases (116 with cytogenetic data) of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Smoking habits were compared with a pooled set of population controls and hospital controls (diagnosed with malignant melanom...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.10.009

    authors: Björk J,Johansson B,Broberg K,Albin M

    更新日期:2009-06-01 00:00:00

  • CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study.

    abstract::Deletion in chromosome 9p involving the CDKN2A locus (9p21.3) is known in many malignancies. To detect this deletion in adolescent ALL patients we used oligo array CGH and studied 54 patients aged 10-25 years. Deletion rate was 25/54 (46%), of these 19/25 (76%) were homozygous. Small deletions (<200 kb) were found in ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.01.014

    authors: Usvasalo A,Savola S,Räty R,Vettenranta K,Harila-Saari A,Koistinen P,Savolainen ER,Elonen E,Saarinen-Pihkala UM,Knuutila S

    更新日期:2008-08-01 00:00:00

  • Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.

    abstract::In a recent phase I study, a combination of gemcitabine at 10 mg/(m(2)min) for 12 h and mitoxantrone 12 mg/m(2) daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refrac...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0145-2126(02)00171-6

    authors: Apostolidou E,Estey E,Cortes J,Garcia-Manero G,Faderl S,Thomas D,Tsimberidou A,Kantarjian H,Giles FJ

    更新日期:2003-04-01 00:00:00

  • Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies.

    abstract::Rearrangements in MLL (MLL-r) are common within very young children with leukemia and affect the prognosis and treatment. Previous studies have suggested the use of the NG2 molecule as a marker for MLL-r but these studies were performed using a small number of infants. We analyzed 148 patients (all less than 24 months...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2011.03.006

    authors: Emerenciano M,Renaud G,Sant'Ana M,Barbieri C,Passetti F,Pombo-de-Oliveira MS,Brazilian Collaborative Study Group of Infant Acute Leukemia.

    更新日期:2011-08-01 00:00:00

  • On the biochemical modulation of 6-mercaptopurine by methotrexate in murine WEHI-3b leukemia cells in vitro.

    abstract::The chemicals 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of acute lymphoblastic leukemia. The intracellular metabolism of 6-MP to 6-thioguanosine nucleotides (TGN) via 6-thioinosine 5'-monophosphate (TIMP) is crucial for its cytotoxic effect. MTX inhibits purine de...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(92)90065-f

    authors: Liliemark J,Pettersson B,Peterson C

    更新日期:1992-01-01 00:00:00

  • Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.

    abstract:BACKGROUND:T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and imp...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.01.009

    authors: Dholaria BR,Ayala E,Sokol L,Nishihori T,Chavez JC,Hussaini M,Kumar A,Kharfan-Dabaja MA

    更新日期:2018-04-01 00:00:00

  • Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.

    abstract::The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis has been used to predict survival in diffuse large B-cell lymphoma (DLBCL) patients, but its prognostic significance with respect to different cell-of-origin (COO) subtypes remains unknown. We retrospectively analyzed 168 de novo DLBCL patients in th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2014.03.013

    authors: Wei X,Huang F,Wei Y,Jing H,Xie M,Hao X,Feng R

    更新日期:2014-06-01 00:00:00

  • Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.

    abstract:OBJECTIVES:Follicular lymphoma (FL) is generally considered an indolent disorder but a significant subset of patients shows a worse outcome. Aim of this study was to validate the FLIPI score in an independent series of follicular lymphoma patients and to correlate prognostic categories with the period of diagnosis and ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.07.006

    authors: Arcaini L,Colombo N,Passamonti F,Burcheri S,Orlandi E,Brusamolino E,Della Porta M,Rumi E,Montanari F,Pascutto C,Paulli M,Lazzarino M

    更新日期:2006-03-01 00:00:00

  • Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.

    abstract::The aim of this study was to evaluate effect of c-KIT mutations on RUNX1/RUNX1T1 fusion transcript expression in patients with t(8;21)-positive AML. Fifty patients diagnosed with t(8;21)-positive AML for recent 10 years were enrolled. Patients with c-KIT mutations tended to achieve a greater than 3-log reduction in RU...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.02.010

    authors: Park SH,Chi HS,Cho YU,Jang S,Park CJ

    更新日期:2013-07-01 00:00:00

  • Caspase-8 dependent apoptosis induction in malignant myeloid cells by TLR stimulation in the presence of IFN-alpha.

    abstract::Pro-apoptotic signalling upon toll-like receptor (TLR) stimulation in myeloid cells is normally antagonized by the simultaneous activation of anti-apoptotic pathways. We have previously reported that IFN-alpha can sensitize human monocytes to apoptosis induction by lipopolysaccharide (LPS). Based on these results we i...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.05.001

    authors: Lehner M,Bailo M,Stachel D,Roesler W,Parolini O,Holter W

    更新日期:2007-12-01 00:00:00

  • Comparison of in vitro and in vivo effects of vincristine and vindesine on leukemic cells from patients with chronic granulocytic leukemia in blast crisis.

    abstract::We employed a liquid culture system to examine the in vitro effects of vincristine and vindesine on cellular incorporation of 35SO4 into leukemic cells obtained from 5 patients with chronic granulocytic leukemia in blast crisis. The per cent of 35SO4 into drug-treated as compared to saline-treated leukemic cells was c...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(84)90062-6

    authors: Theodorakis ME,Goldberg J

    更新日期:1984-01-01 00:00:00

  • Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.

    abstract::Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between chelated and nonchelated patients with lower-risk myelodysplastic syndromes and transfusional iro...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2017.01.033

    authors: Lyons RM,Marek BJ,Paley C,Esposito J,McNamara K,Richards PD,DiBella N,Garcia-Manero G

    更新日期:2017-05-01 00:00:00

  • Bone marrow pre-B expansion by SL/Kh-Bomb1 locus: not sufficient for lymphomagenesis.

    abstract::The pre-B lymphoma in SL/Kh mice is a polygenic trait involving a number of host genes. In prelymphoma-stage bone marrow, transient pre-B cell expansion is induced by a host locus, Bomb1, and later followed by the emergence of a monoclonal population with a similar phenotype. To determine whether these pre-B cells rep...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.05.013

    authors: Hiratsuka T,Tsuruyama T,Kaszynski R,Kometani K,Minato N,Nakamura T,Tamaki K,Hiai H

    更新日期:2008-02-01 00:00:00